Rain Therapeutics to Report Second Quarter 2021 Financial Results and Highlights of Recent Progress on August 10, 2021

NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) — Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter that ended June 30, 2021 and highlights of recent progress, on Tuesday, August 10, 2021. On that day, management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the Company’s business and financial results.

Conference Call and Webcast Details:
Date: August 10, 2021
Time: 1:30 p.m. PT (4:30 p.m. ET)
Dial In Numbers: 1 (800) 708-4539 (U.S. Toll Free) / 1 (847) 619-6396 (U.S. Toll)
Passcode: 50202648
Webcast Link: https://edge.media-server.com/mmc/p/4ar5rh24

The call will be recorded and available for replay on the Company’s website for approximately 30 days after the call.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan (RAIN-32), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. For more information, visit www.rainthera.com.

Media Contact for Rain:
Grace Fotiades
LifeSci Communications
+1.646.876.5026
gfotiades@lifescicomms.com